Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria for all trial participants:~* Age ≥ 18 years at Screening~* Male or female. Women of childbearing potential (WOCBP) participants and male participants able to father a child must be ready and able to use a highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly throughout the Trial~* Mean Arterial Pressure (MAP) ≥ 85 mmHg at screening visit~* Estimated Glomerular Filtration rate (eGFR) \> 70 mL/min/1.73m² according to the CKD-EPI formula at screening visit~* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial~Key inclusion for Patient Groups 1 and 2~* If on treatment with non-selective beta blockers (NSBB), stable dose since ≥ 8 weeks prior to screening, with no planned dose change of the therapy during study conduct. All other medications stable 4 weeks prior to screening.~* Patient Group 1: Patients with CTP A and portal hypertension (defined as liver stiffness \>15 kPa during screening) and without a previous decompensation event \[ascites, variceal hemorrhage, encephalopathy, or jaundice (except Gilbert's disease or hemolysis when bilirubin will be almost exclusively indirect hyperbilirubinemia)\]. Self-limited and resolved historical events of decompensation like ascites or encephalopathy are allowed if they have occurred at least 6 weeks prior to screening and do not require continued therapeutic intervention at the time of screening.~* Patient Group 2: Patients with CTP B (with liver stiffness \>15 kPa during screening)~Key inclusion for Healthy Volunteer group~* Subjects who are healthy, according to the investigator's assessment, individually matched to a participant among Patient Groups 1 and 2 according to the following criteria: age within ± 5 years, body weight within ± 15%, and gender~* Further inclusion criteria apply~Key exclusion for all trial participants~* Ongoing chronic alcohol or drug use, which in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial.~* History of relevant orthostatic hypotension, fainting spells, or blackouts based on the investigator´s judgment~Key exclusion for Patient Groups~* Patient Group 2: treatment-refractory ascites~* Patient Group 2: recent decompensation event (refractory ascites, recurrent variceal hemorrhage, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome) within 6 weeks of screening~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose group 1 (Type: EXPERIMENTAL): Low Dose
- Dose group 2 (Type: EXPERIMENTAL): Medium Dose
- Dose group 3 (Type: EXPERIMENTAL): High Dose
- Dose Group 4 (Type: EXPERIMENTAL): Dose for healthy volunteers dependent on results from prior dose groups with patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete